中文     English
World wide NCE review

World wide NCE review

We have gained the permision from Pharmaphase LTD to publish their worldwide NCE review that list all the NCEs approved from 2001 to 2012.  More specifically for each NCE, the chemical structure, mechanism of action, and its sales in 2012 are listed in this review chart. For moe specific information, please contact BFC Group at david.chen...

New drug development in China

New drug development in China

New drug development in China is still in its early stage, but has gained significant progress in the last five years.  One of the key incentives for new drug development in China is the new government policy towards new drug with IP in China.  These new drugs with composition of matter IP will enjoy independent pricing and no competitive...

TOP 10 Global Pharma MA Deal in 2013

TOP 10 Global Pharma MA Deal in 2013

TOP 10 M&A Cases of Global Pharmaceutical Industry in 2013 Acquiring Company Acquired Company Amount Thermo Fisher Scientific Life Technologies 13.6 billion $ Amgen Onyx Pharmaceutical...

Key M&A Pharma Deal in China in 2013

Key M&A Pharma Deal in China in 2013

Major M&A Cases of Bio-Pharmaceutical Industry in China in 2013   2013.01 Hainan Haiyao acquired 40% equity of China Antibody with 9.9 million dollar to enter the McAb area.   2013.02 Walvax Biotechnology acquired 50.69% equity and increased the capital of Shanghai Zerun Technology with 265 million RMB to enter new recombinant vac...

Hepalink Signs Agreementto Acquire Scientific Protein Laboratories

Hepalink Signs Agreementto Acquire Scientific Protein Laboratories

Shenzhen HepalinkPharmaceutical Co., Ltd. has entered into a stock purchase agreement to acquireScientific Protein Laboratories, LLC. (SPL), a leading global, independentmanufacturer and supplier of active pharmaceutical ingredients (APIs).  This acquisition will make Hepalink a globalsupplier of Heparin. “Thisrepresents an exciting oppo...

FREE NEWSLETTER
Email address: